ANDERSON EXHIBIT 18G



Savings: Up to 4% Rebate*

Item Description	Strength	Size	NDC#	Compared to:	CIN#	DP#
Premarin Tabs	0.3 mg	100	00046-0868-81	HRT Products	1124478	008567
Premarin Tabs	0.3 mg	1000	00046-0868-91	HRT Products	1007723	008575
Premarin Tabs	0.625 mg	100	00046-0867-81	HRT Products	1200864	841331
Premarin Tabs	0.625 mg	1000	00046-0867-91	HRT Products	1095751	008559
Premarin Tabs	0.625 шд	5000	00046-0867-95	HRT Products	1049535	433683
Premarin Tabs	0.625 mg	100 UD	00046-0867-99	HRT Products	1005461	154903
Premarin Tabs	0.9 mg	100	00046-0864-81	HRT Products	1285857	008591
Premarin Tabs	1,25 mg	100	00046-0866-81	HRT Products	1538362	841340
Premarin Tabs	1,25 mg	1000	00046-0866-91	HRT Products	1124452	008524
Premarin Tabs	1.25 mg	5000	00046-0866-95	HRT Products	1049451	433.691
Premarin Tabs	1.25 mg	100 UD	00046-0866-99	HRT Products	0120062	116416
Premarin Tabs	2.5 mg	100	00046-0865-81	HRT Products	1669282	902500
Premarin Tabs	2.5 mg	· 1000	00046-0865-91	HRT Products	1326693	008494
Premphase	0.625mg/5mg	3 cartons	00046-2573-02	HRT Products	2412815	163937
Premphase	0.625mg/2.5mg	3x(2x14)	00046-0875-02	HRT Products	2412807	163953
<baselin< td=""><td>ne Market Share</td><td></td><td></td><td>* Rebate will be rec</td><td>eived as an</td><td>off invoice</td></baselin<>	ne Market Share			* Rebate will be rec	eived as an	off invoice
To 2.49%	Above Baseline	0		in October of 199	8.	
2.5% - 2.99%	Above Baseline	1.25%				
3.0% - 3.49%	Above Baseline	1.75%		** This rebate is being	ng tracked by	y NDC.
3.5% - 3.99%	Above Baseline	2,50%				
4.0% - 4.99%	Above Baseline	3.25%				
≥5.0%	Above Baseline	4.00%				

Each Leader member must sign an agreement to be eligible, if you have not done so, please contact your sales consultant.

July - September 1999

Effective: 4-1-98 - 3-31-01

44



Up to 31% Rebate* Savings:

Effective: 4-1-98 - 3-31-01

Item Description	Strength	Size	NDC#	Compared to:	CIN#	DP#
Alesse - 21		3 x 21	00008-0912-02	All Oral Contraceptives All Oral	2570968	257096
Alesse - 28		3 x 28	00008-2576-02	Contraceptives All Oral	2565679	256567
Lo/Ovral Tab		6 x 21	00008-0078-01	Contraceptives All Oral	1022052	096660
Lo/Ovral - 28 Tabs		6 x 28	00008-2514-02	Contraceptives All Oral	1239821	966679
Nordette Tab		6 x 21	00008-0075-01	Contraceptives All Oral	1080548	096717
Nordette - 28 Tab		6 x 28	00008-2533-02	Contraceptives All Oral	1123678	096725
Triphasil - 21		3 x 21	00008-2535-01	Contraceptives All Oral	1379858	097268
Triphasil - 28		3 x 28	00008-2536-01	Contraceptives	1379866	097284

	<baseline market="" share<="" th=""><th></th></baseline>	
To 3.749%	Above Baseline	0
3.75% - 5.749%	Above Baseline	9.0%
5.75% - 7.99%	Above Baseline	14.5%
8.0% - 10.49%	Above Baseline	19.8%
10.5% - 11.99%	Above Baseline	25.5%
≥ 12%	Above Baseline	31.0%

^{*} Rebate will be received as an off invoice starting in October of 1998.

Each Leader member must sign an agreement to be eligible, if you have not done so, please contact your sales consultant.

July - September 1999

45

0

0 4

> 1 •

^{**} This rebate is being tracked by NDC.





•

Manufacturer: Wyeth-Ayerst

Effective: 4-1-98 - 3-31-01

Savings:

Up to 13.25% Rebate*

Item Description	Strength	Size	NDC#	Compared to:	CIN#	DP#	
Ziac Tabs	2.5mg/6.25mg	100	00005-3238-23	Cardiovascular Products Cardiovascular	1984194	878853	
Ziac Tabs	5mg/6.25mg	100	00005-3234-23	Products Cardiovascular	1984202	873861	
Ziac Tabs	10mg/6.25mg	30	00005-3235-38	Products Non-Narcotic	1984210	873870	
Duracet Capsules		100	00008-0909-01	Analgesics	2580413	258041	
Lodine XL Tabs	400 mg	100	00046-0829-81	All NSAIDs	2513778	629499	
Lodine XL Tabs	600 mg	100	00046-0831-81	All NSAIDs	2513786	490008	
Naprelan Tabs	375 mg	100	00008-0901-03	All NSAIDs	2444594	263605	
Naprelan Tabs	500 mg	75	00008-0902-02	All NSAIDs	2444602	263613	
Zi ac <b< td=""><td>aseline Market Share</td><td></td><td></td><td>Duracet <</td><td>Baseline Mark</td><td></td><td></td></b<>	aseline Market Share			Duracet <	Baseline Mark		
Го 0.99%	Above Baseline		0	To 9.99	Above Base		0
1.0% - 1.99%	Above Baseline		2.50%	10.0% - 14.99%	Above Base		4.00 6.25
2.0% - 2.99% 3.0% - 3.99%	Above Baseline Above Baseline		5.00% 7.75%	15.0% - 19.99% 20.0% - 24.99%	Above Base		8.75
3.0% - 3.99% 4.0% - 4.99%	Above Baseline Above Baseline		10.50%	20.0% - 24.99% ≥25.0%	Above Base		11.0
≥5.0%	Above Baseline		13.25%	223.070	LUOTO Das	J1110	11.0
Lodine & Naprela		t Share		* Rebate will be re		off invoic	e sta
To 0.99%	Above Baseline		0	in October of 19	98.		
1.0% - 1.99%	Above Baseline		3.00%	44 mi ! ! ! . !		. NTOC	
2.0% - 2.99%	Above Baseline		4.50%	** This rebate is be	ing tracked by	y NDC.	
3.0% - 3.99%	Above Baseline Above Baseline		6.25%				
4.0% - 4.99%	Above Baseline Above Baseline		8.75% 11.50%				
≥ 5.0%	Above baseinie		11.3070				

Each Leader member must sign an agreement to be eligible, if you have not done so, please contact your sales consultant.

July - September 1999



Savings: Up to 8.7% Rebate*

Effective: 4-1-98 - 3-31-01

Item Description	Strength	Size	NDC#	Compared to:	CIN#	DP#
Effexor Tabs	25 mg	100	00008-0701-01	Antidepressants & SSRI, SNRI Antidepressants &	2061190	888389
Effexor Tabs	25 mg	10 x 10	00008-0701-02	SSRI, SNRI Antidepressants &	2061216	888672
Effexor Tabs	37.5 mg	100	00008-0781-01	SSRI, SNRI Antidepressants &	2061224	888397
Effexor Tabs	37.5 mg	10 x 10	00008-0781-02	SSRI, SNRI Antidepressants &	2061232	888680
Effexor Tabs	50 mg	100	00008-0703-01	SSRI, SNRI Antidepressants &	2061240	888400
Effexor Tabs	50 mg	10 x 10	00008-0703-02	SSRI, SNRI Antidepressants &	2061257	888699
Effexor Tabs	75 mg	100	00008-0704-01	SSRI, SNRI Antidepressants &	2061265	888419
Effexor Tabs	75 mg	10 x 10	00008-0704-02	SSRI, SNRI Antidepressants &	2061273	888702
Effexor Tabs	100 mg	100	.00008-0705-01	SSRI, SNRI Antidepressants &	2061299	888427
Effexor Tabs	100 mg	10 x 10	00008-0705-02	SSRI, SNRI Antidepressants &	2061307	888710
Effexor XR Cap	37.5 mg	100	00008-0837-01	SSRI, SNRI Antidepressants &	2700672	010911
Effexor XR Cap	75 mg	.100	00008-0833-01	SSRI, SNRI Antidepressants &	2700680	731950
Effexor XR Cap	150 mg	100	00008-0836-01	SSRI, SNRI	2700706	731968
			<baseline marke<="" td=""><td>t Share</td><td></td><td></td></baseline>	t Share		
		To 0.99%	Above Baseline	0		
		1.0% - 1.99%	Above Baseline	2.00%		
		2.0% - 2.99%	Above Baseline	3.00%		
		3.0% - 3.99%	Above Baseline	5.00%		
		4.0% - 4.99%	Above Baseline	6.75%		

Each Leader member must sign an agreement to be eligible, if you have not done so, please contact your sales consultant.

≥5.0% Above Baseline 8.70%

July - September 1999

47

•

•

^{*} Rebate will be received as an off invoice starting in October of 1998.

^{**} This rebate is being tracked by NDC.



Savings: Up to 10.7% Rebate*

Effective: 4-1-98 - 3-31-01

Item Description	Strength	Size	NDC#	Compared to:	CIN#	DP#	
Verelan Cap	120 mg	100	00005-2490-23	Calcium Channel Blockers Calcium Channel	1832278	697748	
Verelan Cap	180 mg	100	00005-2489-23	Blockers	1776525	7.61254	
Verelan Cap	240 mg	100	00005-2491-23	Calcium Channel Blockers Calcium Channel	1832286	697755	
Verelan Cap	360 mg	100	00005-2495-23	Blockers	2475507	627067	
Suprax Tabs	200 mg	100	00005-3899-23	Antibiotic Tablets	1741115	644595	
Suprax Tabs	400 mg	10	00005-3897-94	Antibiotic Tablets	1255892	541532	
Suprax Tabs	400 mg	50	00005-3897-18	Antibiotic Tablets	1719012	675280	
Suprax Tabs	400 mg	100	00005-3897-23	Antibiotic Tablets	1719004	019151	
Suprax Tabs	400 mg	10 x 10	00005-3897-60	Antibiotic Tablets Antibiotic	1128107	805238	
Suprax Suspension	100mg/5mg	50 mL	00005-3898-40	Suspensions Antibiotic	1719038	675298	
Suprax Suspension	100mg/5mg	75 mL	00005-3898-42	Suspensions Antibiotic	2097608	753152	
Suprax Suspension	100mg/5mg	100 mL	00005-3898-46	Suspensions	1719020	675306	
Verelan <bas< td=""><td>eline Market Share</td><td></td><td></td><td>Suprax Tabs <b< td=""><td>aseline Mark</td><td>et Share</td><td></td></b<></td></bas<>	eline Market Share			Suprax Tabs <b< td=""><td>aseline Mark</td><td>et Share</td><td></td></b<>	aseline Mark	et Share	
To 3.749%	Above Baseline		0	To 0.99%	Above Base	line	.0
3.75% - 5.749%	Above Baseline		4.50%	1.0% - 1.49%	Above Base	line	5.00%
5.75% - 8.249%	Above Baseline		5.70%	1.50% - 1.99%	Above Base	line	6.50%
8.25% - 10.49%	Above Baseline		7.00%	2.0% - 2.49%	Above Base	line	7.70%
10.5% - 11.99%	Above Baseline		8.50%	2.5% - 2.99%	Above Base	line	8.80%
≥ 12.0%	Above Baseline		10.00%	≥ 3.0%	Above Base	line	10.70%
Suprax Suspension	<baseline market="" s<="" td=""><td>hare</td><td></td><td>* Rebate will be re</td><td>ceived as an</td><td>off invoic</td><td>e starting</td></baseline>	hare		* Rebate will be re	ceived as an	off invoic	e starting
To 0.99%	Above Baseline		0	in October of 199	8.		
1.0% - 1.99%	Above Baseline		2.50%	** This rebate is bei	ng tracked by	NDC.	
2.0% - 2.99%	Above Baseline		3.00%				
3.0% - 3.99%	Above Baseline		4.25%	Each Leader membe	_	-	
4.0% - 4.99%	Above Baseline		5.70%	be eligible, if you ha		io, please	contact
≥5.0%	Above Baseline		7.80%	your sales consultan	t.		

July - September 1999

48

6

()



Manufacturer: Zeneca Pharmaceuticals

Savings: Up to 43% Rebate

Effective: 7-1-97 - 6-30-00

Item Description	Strength	Size	NDC#	Compared to:	CIN#	DP#
Zestril	2.5 mg	100	00310-0135-10	Prinivil	2415339	188859
Zestril	5 mg	100	00310-0130-10	Prinivil	1475268	574279
Zestril	5 mg	1000	00310-0130-34	Prinivil	1679059	791059
*Zestril	10 mg	100	00310-0131-10	Prinivil	1475284	574287
Zestril	10 mg	1000	00310-0131-34	Prinivil	1679042	791067
*Zestril	20 mg	100	00310-0132-10	Prinivil	1475300	574295
Zestril	20 mg	1000	00310-0132-34	Prinivil	1678994	791075
Zestril	40 mg	100	00310-0134-10	Prinivil	1585280	616265
Zestril	30 mg	100	00310-0133-10	Prinivil	2842102	284210

Key Facts:

0

0 0 0

Zestril is AB rated and is a cost effective alternative to Prinivil.

Zestril Profit Analysis vs. Competitive Item:

,					Contract	
Preferred Product	UM	AWP	Direct Cost	AWP Less 12%	Cost**	Profit Per Unit
Zestril 10mg	100	\$87.92	\$73.27	\$77.37	\$39.63	F \$37.94
				1		Dec St Don Unit

							and the second s
-	Competing Product	UM	AWP	Direct Cost	AWP Less 12%	Net Sell	Profit Per Unit
	Prinivil 10 mg		\$87.16	\$72.63	\$76.70	\$72.63	\$4.07

^{**} Contract cost after rebate, assuming the highest attainable rebate is achieved.

Pharmacist Action Steps:

- Product is AB rated, fill the preferred item.
- This contract will be using Leader total unit volume, allowing you to take full advantage of the highest attainable market share percentages.
- Market share is calculated on tablets dispensed which is being tracked by NDC.

Each Leader member must sign an agreement to be eligible, if you have not done so, please contact your sales consultant, or see page 50 to sign up.

Rebates are calculated on Leader as a group.

49

July - September 1999



Manufacturer: Zeneca Pharmaceuticals (Continued)

Savings:

Up to 43% Rebate

Effective: 7-1-97 - 6-30-00

Item Description	Strength	Size	NDC#	Compared to:	CIN#	DP#
Zestoretic	10/12.55 mg	100	00310-0141-10	Prinzide	2466639	941093
Zestoretic	20/12 mg	100	00310-0142-10	Prinzide	2466613	623423
Zestoretic	20/25 mg	100	00310-0145-10	Prinzide	2466621	623415

Zestril/Zestoretic Quarterly Tablet Volume ('000s)

Achieved Market Share	<100	≥ 100	≥350	≥ 750	≥ 1500
	7 7 7	7			
< 20%	0.00%	0.00%	0.00%	0.00%	0.00%
≥ 20%	0.50%	1.00%	1.25%	2.00%	3.00%
≥ 25%	3.00%	3.50%	3.75%	4.75%	5.75%
≥ 30%	5,50%	6.00%	6,25%	7.50%	8.75%
≥35%	8.00%	8.50%	8.75%	10.25%	11.75%
≥ 40,%	10.50%	11.00%	11.25%	13.00%	14.25%
≥ 45%	13.25%	13.75%	14,00%	15.75%	16.75%
≥ 50%	16.00%	16.50%	16.75%	18.50%	19.25%
≥:55%	18.75%	19.25%	19.50%	21.25%	21.75%
≥60%	21.50%	22.00%	22.25%	24.00%	24.25%
≥65%	24.25%	24.75%	25.00%	26.75%	27.25%
.≥70%	27.00%	27.50%	27.75%	29.50%	30.25%
≥75%	29.75%	30.25%	30.50%	32.25%	33.25%
≥80%	32.50%	33.00%	33.25%	35.00%	36.25%
≥ 85%	35.25%	35.75%	36.00%	37.75%	39.25%
≥90%	38.00%	38.50%	38.75%	40.50%	42.25%
≥95%	40.75%	41.25%	41.50%	43.25%	43.75%


Each Leader member must sign an agreement to be eligible, if you have not done so, please contact your sales consultant, or see page 50 to sign up.



July - September 1999

50

CH 055728



SINGLE GROUP DEDICATION DECLARATION

In compliance with the Zeneca P	harmaceuticals' Sing	le Group Dedication					
(Pharmacy Name) Leader Drug-Cardinal Health-WPN as the exclusive buying group for purposes of (Buying Group/Co-op/PSAO/WPN) eligibility for the Zeneca Pharmaceuticals' Performance Incentive Reimbursement Contract.							
This document will serve as written confirmation of single group of choice, and will remain on file and in effect until further signed written confirmation of a change has been received by Zeneca. Changes in designation will only be accepted on a Zeneca Pharmaceuticals' Single Group Dedication Declaration Form.							
ALL INFO	RMATION MUST BE	FILLED OUT					
(Signature)	(Pharmacy Name)						
(Printed Name)	(Address)	*					
(Title)	(City, St., ZIP)	and the second s					
(Date)	(DEA #)	(NABP #)					
(Phone #)	(FAX #)						
Upon completion, please mail or	Fax a copy to the fol	llowing;					
Cardinal Distribution, 7000 Cardinal Pl., Dublin, OH 43017, ATTN; Elisabeth Grunwald FAX: 614-757-8228							
*Zeneca Pharmaceuticals is a business unit of Zeneca Inc.							

July - September 1999

51

0

(1)